- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 17, 2007
Highlights
- Market Cap
- $69.72M
- Enterprise Value
- $5.90M
- EPS (TTM)
- -$14.67
- EBITDA (TTM)
- -$41.46M
- Year Range
- $6.27 - $39.75
- Target Price
- $18.00
- ROA (TTM)
- -60.25%
- ROE (TTM)
- -66.89%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PMN Performance Chart
ProMIS Neurosciences Inc. (PMN) is up 56.5% since the beginning of the year. At $11 per share, PMN is trading 73.1% below its 52-week high of $40. Investors who bought $1,000 worth of PMN shares 5 years ago would now be looking at an investment worth $2,556.
Loading charts...
Returns By Period
ProMIS Neurosciences Inc. (PMN) has returned 56.48% so far this year and -14.56% over the past 12 months. Over the last ten years, PMN has had an annualized return of 13.47%, just under the S&P 500 Index benchmark’s 13.88%.
ProMIS Neurosciences Inc.
- 1D
- 1.33%
- 1M
- -2.73%
- YTD
- 56.48%
- 6M
- 31.37%
- 1Y
- -14.56%
- 3Y*
- -52.94%
- 5Y*
- 20.65%
- 10Y*
- 13.47%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
PMN Monthly Returns History
Based on dividend-adjusted daily data since Jul 17, 2007, PMN's average daily return is +1.57%, while the average monthly return is +27.58%. At this rate, an investment would double in approximately 0.2 years.
Historically, 37% of months were positive and 63% were negative. The best month was Jul 2022 with a return of +5,851.0%, while the worst month was Mar 2015 at -73.2%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 6 months.
On a daily basis, PMN closed higher 24% of trading days. The best single day was Jul 1, 2022 with a return of +6,762.8%, while the worst single day was Nov 6, 2008 at -69.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 107.47% | 66.03% | -45.98% | -13.07% | -2.08% | -1.20% | 56.48% | ||||||
| 2025 | -4.04% | -21.94% | -2.04% | -10.87% | -16.12% | -6.96% | 59.38% | -29.98% | -21.28% | -2.33% | -34.86% | 0.96% | -71.20% |
| 2024 | 73.91% | 4.50% | -8.61% | 4.87% | -8.04% | -18.57% | -4.33% | -4.79% | -8.51% | 1.60% | -25.98% | 0.83% | -17.58% |
| 2023 | 19.59% | -1.16% | -7.80% | 45.45% | -28.91% | -20.68% | -26.03% | -31.71% | 1.04% | -11.63% | -33.14% | -1.71% | -73.50% |
| 2022 | -4.27% | -5.03% | 0.10% | -10.09% | -0.33% | 13.71% | 5,850.98% | -7.74% | 9.46% | -4.57% | -3.08% | -23.46% | 3,845.45% |
| 2021 | -0.36% | 25.79% | 62.27% | -15.78% | 22.46% | -3.11% | -7.48% | 2.63% | -10.09% | 3.23% | -27.27% | 1.85% | 32.69% |
Benchmark Metrics
ProMIS Neurosciences Inc. has an annualized alpha of 4379.85%, beta of 1.29, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 17, 2007.
- This stock participated in 174.45% of S&P 500 Index downside but only 139.89% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 4,379.85%
- Beta
- 1.29
- R²
- 0.00
- Upside Capture
- 139.89%
- Downside Capture
- 174.45%
Return for Risk
Risk / Return Rank
PMN ranks 48 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for ProMIS Neurosciences Inc. (PMN) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PMN | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.11 | ||
| Sortino ratioReturn per unit of downside risk | -1.38 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 1.37 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | -0.19 | 2.78 | -2.98 |
| Martin ratioReturn relative to average drawdown | -0.26 | 12.44 | -12.70 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the ProMIS Neurosciences Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the ProMIS Neurosciences Inc. was 98.80%, occurring on Mar 26, 2015. Recovery took 1823 trading sessions.
The current ProMIS Neurosciences Inc. drawdown is 95.38%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2015 bear market2015 | -98.80%Mar 2015 | 7y 7mo | 7y 3mo | 14y 11moAug 2007 - Jul 2022 |
2025 bear market2025 | -97.08%Nov 2025 | 3y 4mo | — | 3y 11moJul 2022 - now |
Bear market2022 | -9.29%Jul 2022 | 1d | 2d | 3dJul 2022 - Jul 2022 |
2007 pullback2007 | -7.75%Jul 2007 | 1d | 1d | 2dJul 2007 - Jul 2007 |
Drawdown Indicators
| PMN | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.80% | -56.78% | -42.02% |
Max Drawdown (1Y)Largest decline over 1 year | -75.86% | -9.10% | -66.76% |
Max Drawdown (3Y)Largest decline over 3 years | -95.63% | -18.90% | -76.73% |
Max Drawdown (5Y)Largest decline over 5 years | -97.08% | -25.43% | -71.65% |
Max Drawdown (10Y)Largest decline over 10 years | -97.08% | -33.92% | -63.16% |
Current DrawdownCurrent decline from peak | -95.38% | -1.80% | -93.58% |
Average DrawdownAverage peak-to-trough decline | -76.43% | -10.71% | -65.72% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 55.34% | 2.03% | +53.31% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of ProMIS Neurosciences Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how ProMIS Neurosciences Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PMN in comparison with other companies in the Biotechnology industry. Currently, PMN has a P/B value of 1.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PMN
Add ProMIS Neurosciences Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PMN